Surmodics (NASDAQ:SRDX) Releases FY 2025 Earnings Guidance

Key Points

• Surmodics updated its FY 2025 earnings guidance, expecting earnings per share (EPS) of -0.350 to -0.200 and revenue of $116.5 million to $118.5 million, surpassing consensus estimates.
• The stock opened at $35.01 and has a market cap of $500.64 million, reflecting a P/E ratio of -25.19.
• Institutional investors and hedge funds hold 96.63% of Surmodics' stock, with a recent purchase of 4,000 shares by Strs Ohio valued at approximately $122,000.

Surmodics (NASDAQ:SRDX - Get Free Report) issued an update on its FY 2025 earnings guidance on Friday morning. The company provided EPS guidance of -0.350--0.200 for the period, compared to the consensus EPS estimate of -0.546. The company issued revenue guidance of $116.5 million-$118.5 million, compared to the consensus revenue estimate of $115.7 million.

Surmodics Stock Performance

Shares of SRDX stock traded down $0.15 during trading hours on Tuesday, reaching $37.85. 93,171 shares of the company traded hands, compared to its average volume of 177,237. The firm has a 50-day moving average price of $31.44 and a 200 day moving average price of $30.78. The company has a debt-to-equity ratio of 0.27, a current ratio of 3.91 and a quick ratio of 3.10. Surmodics has a 12-month low of $26.00 and a 12-month high of $40.38. The company has a market cap of $541.26 million, a P/E ratio of -30.78 and a beta of 1.31.

Surmodics (NASDAQ:SRDX - Get Free Report) last announced its quarterly earnings data on Friday, August 8th. The company reported $0.06 EPS for the quarter, beating the consensus estimate of ($0.21) by $0.27. Surmodics had a negative return on equity of 3.04% and a negative net margin of 14.59%. The company had revenue of $29.57 million for the quarter, compared to the consensus estimate of $28.04 million. As a group, sell-side analysts predict that Surmodics will post 0.2 earnings per share for the current fiscal year.

Analysts Set New Price Targets

SRDX has been the subject of several analyst reports. Needham & Company LLC reaffirmed a "hold" rating on shares of Surmodics in a research note on Wednesday, April 30th. Barrington Research restated a "market perform" rating on shares of Surmodics in a report on Monday.

Institutional Trading of Surmodics

Institutional investors have recently modified their holdings of the business. Strs Ohio purchased a new stake in shares of Surmodics in the first quarter worth $122,000. Creative Planning acquired a new position in Surmodics in the second quarter valued at approximately $318,000. Finally, Millennium Management LLC increased its holdings in Surmodics by 71.6% in the first quarter. Millennium Management LLC now owns 206,487 shares of the company's stock valued at $6,304,000 after buying an additional 86,143 shares during the last quarter. 96.63% of the stock is currently owned by hedge funds and other institutional investors.

Surmodics Company Profile

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).